New Potential Chemotherapy for Ovarian Cancer: Combined Therapy with WP 631 and Epothilone B

The document from April 1, 2016, explores a new chemotherapy combination for ovarian cancer treatment using WP 631, a bisanthracycline, and Epothilone B (Epo B), a macrolide. The combination has shown synergistic effects, enhancing apoptosis in ovarian cancer cells more effectively than either drug alone by disrupting cell cycle-regulating proteins, leading to mitotic slippage, and affecting the expression of proteins such as EpCAM and HMGB1 associated with poor prognosis. While promising, the document calls for further investigation into the toxicity profile of this combination before it can be advanced for clinical research. The study was supported by the Ministry of Science and Higher Education in Poland, and no conflicts of interest were reported.